AstraZeneca Reports Phase 3 subgroup analysis Data for Zavegepant in Severe uncontrolled asthma

AstraZeneca today announced Phase 3 subgroup analysis results for Zavegepant in patients with Severe uncontrolled asthma. The study demonstrated that Zavegepant reduces exacerbation rates significantly compared to standard of care or placebo. These results provide important insights into the treatment of Severe uncontrolled asthma and support the continued development of Zavegepant in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Zavegepant was consistent with previous observations, with no new safety signals identified.